CSL Ltd (ASX: CSL) shares have staged a remarkable comeback, surging 35% in the past month and gaining 94% from their 52-week low in June.

But zoom out, and the picture looks less spectacular. CSL shares remain about 16% lower over the past 12 months.

So, after such a powerful rebound, where do experts think the biotech giant could go from here?

What do brokers think?

Not every broker believes the recovery is firmly established. Of 19 analysts tracked on TradingView, 10 rate CSL shares a hold, while nine have a buy or strong-buy rating.

More importantly, the average 12-month price target is $171.94, below the share price of $174.50 at the time of writing.

However, forecasts vary dramatically. The most bullish target sits at $206.86, implying another 19% upside, while the lowest is just $131.56, pointing to roughly 25% downside.

Macquarie is among the most bearish, with a neutral rating and target of just over $133. UBS is considerably more optimistic at $181, while Morgan Stanley has a $172 target.

Bell Potter has retained its hold rating on the ASX biotech stock but recently increased its target from $120 to $150.

Why have CSL shares soared?

The catalyst was CSL’s FY26 result. On the surface, it looked ugly, with the $80 billion biotech company reporting a US$2.6 billion net loss after tax.

But investors quickly looked beyond the headline number.

The loss included US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs, much of which was non-cash. Most impairments related to CSL Vifor intangibles and under-utilised property, plant and equipment.

Investors had already received a warning in May, when CSL flagged around US$5 billion of impairments and cut its FY26 guidance.

Excluding exceptional items, underlying NPATA was US$3.1 billion, down just 2%. Revenue fell 1% to US$15.8 billion but still beat analyst expectations.

For investors, the result therefore represented something potentially more valuable than headline profit: a reset year, cleaner balance sheet and better-than-feared outlook.

CSL Behring remains the standout. Its plasma division generated US$11.4 billion of revenue, while immunoglobulin revenue held steady at US$6.2 billion. CSL Vifor grew revenue 3% to US$2.4 billion, although Seqirus remained under pressure, with revenue falling 8% to US$2 billion.

Could FY27 send the biotech stock higher?

The bull case centres on FY27. CSL expects underlying NPAT to grow approximately 5%, ahead of consensus expectations of around 2%.

Behring is forecast to deliver mid-single-digit growth, with immunoglobulins expected to grow at a mid-to-high single-digit rate.

The major challenge remains Vifor, where revenue is expected to plunge about 25% as iron generics enter the market.

For CSL shares, the recovery story is clearly gaining momentum. The question now is whether improving fundamentals can justify the renewed optimism already priced into the stock.

The post CSL shares are up 94% from their low. What are brokers forecasting next? appeared first on The Motley Fool Australia.

More reading

• Looking to bank the upcoming CSL dividend? You better hurry!
• Top 3 ASX healthcare shares to buy after a brutal year
• Top 3 ASX shares I’d buy with $5000 right now
• 40 ASX shares with ex-dividend dates next week
• ASX shares investors are getting younger and trading more often: CBA report

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The ASX dividend stock Charter Hall Long WALE REIT (ASX: CLW) has fallen steeply – it’s down 35% since April 2022 and 22% in the past year. I think this is a great time to look at the real estate investment trust (REIT) at such a cheap price.  

This business has several positives, and I think this period of higher interest rates has created an excellent buying opportunity for brave investors.

It’s invested in a number of areas including service stations, telecommunication exchanges, data centres, government-related buildings (such as Geosciences Australia), hotels/pubs and so on.

When share prices fall, investors get the chance to buy at a better yield. That’s exactly what’s happening here. So, let’s run through why it’s an appealing buy.

Strong dividend yield

One of the most pleasing elements of this business is how it operates with a distribution payout ratio of 100% of its net rental earnings, unlocking a very strong distribution yield for investors.

However, REITs typically have sizeable amounts of debt on their balance sheets as a way to partially fund their commercial property investments. So, it’d be understandable if some names in the sector face lower rental earnings and a lower distribution in FY27.

But, thanks to the resilience of the ASX dividend stock’s operations and compelling rental contract agreements, the business has guided that it will be able to maintain its FY27 annual payout at 25.5 cents per security.

That means the business could pay a distribution yield of 7.25% in FY27.

Pleasing rental growth

One of the reasons why the business has been able to maintain its dividend payout is because it has pleasing rental growth built into its contracts with tenants.

Rental growth is built into the rental contracts, with increases either fixed annually or tied to inflation. With consistent growth, the business can deliver stable, growing payouts over time.

Not only does the business achieve regular rental growth, but its tenants are signed on for a very long time, on average. It currently has a weighted average lease expiry (WALE) of around nine years. That means it can offer investors both long-term income visibility and security.  

Very attractive valuation for the ASX dividend stock

Not only is there a good yield, diversification and decent growth on offer, but I think it’s also undervalued.

The business reported that on 30 June 2026, its net tangible assets (NTA) was $4.71 per unit, which was a year-over-year increase of 2.6%. The NTA includes the value of the properties, the loans, cash and all the other tangible assets and liabilities.

That $4.71 valuation per unit is based on the entire property portfolio being independently valued during the financial year. At the time of writing, the ASX dividend stock is valued at 25% discount, so I think it’s a great time to invest.

I think Charter Hall Long WALE REIT is one of the best value stocks around, though it’s not the only one.

The post 1 ASX dividend stock down 35% I’d buy right now appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $60,000 annual passive income?
• 3 strong ASX dividend shares with yields up to 7.7%
• How much is needed in superannuation to target a $2,500 monthly passive income?
• How to build an ASX portfolio you do not need to check every day
• How much is needed in superannuation to target a $5,500 monthly passive income?

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Four heavyweight S&P/ASX 50 Index (ASX: XFL) shares have been hammered over the past 12 months, falling between 30% and 60%.

Each ASX 50 share has faced different challenges, but with brokers still seeing substantial upside in several names, investors may be wondering whether the sell-offs have gone too far.

Xero Ltd (ASX: XRO)

The Xero share price has taken a beating, but the business itself continues to grow at a healthy pace. This ASX 50 share delivered FY26 operating revenue of NZ$2.75 billion, up 31%, while annualised monthly recurring revenue jumped 37% to NZ$3.27 billion.

Xero added 506,000 customers during the year, taking its global base to 4.92 million. Management expects another strong year, with FY27 revenue guidance of NZ$3.62 billion to NZ$3.73 billion, implying around 30% growth at the midpoint.

There also appears to be plenty of runway, with Xero previously estimating a total addressable market of around 100 million small and medium-sized businesses.

Brokers remain divided. Citi has a buy rating and $113.60 target, while Morgan Stanley sees $130 and UBS $127. Ord Minnett and Morgans have targets of $110 and $111 respectively. RBC Capital and Jefferies are more cautious, with targets of $85 and $77.

WiseTech Global Ltd (ASX: WTC)

Few ASX 50 shares have experienced a more dramatic rollercoaster than WiseTech. Its shares have traded as high as $135 and as low as $28.76, representing an almost 80% peak-to-trough decline.

At around $37.57 at the time of writing, the stock remains close to its lows after falling approximately 60% over 12 months.

Yet the underlying business continues to grow. WiseTech reported a 46% increase in EBITDA to US$558.4 million for FY26, broadly within its guidance range.

Brokers appear considerably more optimistic than the share price suggests. Macquarie has an outperform rating and $48.20 target, while Citi and UBS have buy ratings with targets of $58.75 and $56 respectively.

Pro Medicus Ltd (ASX: PME)

AI concerns helped hammer this ASX 50 share, but the underlying numbers remain impressive.

Pro Medicus delivered FY26 revenue growth of 22.9% to $261.7 million, while underlying EBIT and NPAT rose 24.4% and 24.1% respectively.

Its Visage imaging software is already used by major healthcare systems across North America, yet management estimates it has captured only around 11% of the US market.

Citi has a buy rating and $225 target, implying around 34% upside. Barrenjoey has a buy recommendation with a $210 target, while JPMorgan is more cautious with a hold rating and $211 target.

REA Group Ltd (ASX: REA)

REA Group has also been under pressure, with this ASX 50 share trading around $168, well below its 52-week high of $242.81.

FY26 revenue increased 7% to $1.79 billion, although net profit fell 19%, partly due to an impairment relating to REA India.

The bigger concern is FY27, with REA warning that new national buy listings could be flat to down by low single digits.

Still, several brokers see value. Morgan Stanley has a $230 target, which points to a 37% upside. This is followed by Ord Minnett at $225 and Morgans at $203. RBC, Jefferies and UBS have targets ranging from $177 to $197.

Macquarie is more cautious at $170, while Bell Potter has a sell rating and $147 target. This suggests a potential loss of 12% at the current share price level.

The post These ASX 50 shares have lost up to 60%. Is the sell-off overdone? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Monday
• How to build a winning ASX share portfolio and create wealth
• Top 3 ASX healthcare shares to buy after a brutal year
• 9 ASX shares downgraded by experts post-results this week
• Down another 18%: Why I’d buy WiseTech shares in the dip

Citigroup is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended JPMorgan Chase, Macquarie Group, WiseTech Global, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended Macquarie Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.